Coalesce Research Group invites all pharmaceutical and Medical researchers, professionals, faculties and students the from across the globe to attend "International Conference on Biosimilars and Biologics" during April 20-21, 2020 at Dubai, UAE which includes keynote presentations from highly affiliated personalities, Oral talks, Poster presentations, and Exhibitions.
Event Date : 20 - 21 April 2020
Location : Dubai, UAE
ICBB-2020 focuses on "The Present Scenario and Future Prospects of Biosimilars & Biologics". This biologics meeting focuses on the trends which the biosimilar markets are heading on since its launch till the present date and moving on to the projections in the future. It takes into its fold the critical developmental procedures, analyses, regulatory factors and also pharmacovigilance including post-marketing surveillance and clinical studies. Innovation and compliance with regulatory guidelines are the most critical aspects toward's biosimilars and follow on biologics development and successful launching to the market.
Current Challenges in Developing Biosimilars and Biologics, Emerging Biosimilars in Therapeutics, Biosimilars Analytical Strategies, Regulatory Approach for Biosimilars, Globalization of Biosimilars, Biosimilars Role in Oncology and Gastroenterology, Biologics and Biosimilars in inflammatory bowel disease, Biosimilars vs Biologics, Biosimilars vs Generics, Biologics as therapeutics, Immunogenicity of Biosimilars, Intellectual Property Rights, Monoclonal Antibody and Fusion Protein Biosimilars, BCS and IVIVC Based Biowaivers, Biosimilar Companies and Market Analysis, Legal Issues and BPCI Act, Biosimilars Research Pipeline, Bioequivalence Assessment, Biopharmaceuticals and Biotechnology, Current Trends in Pharmaceutical industry and Biosimilars in Rheumatology and Dermatology
At the moment, the uptake of biosimilars is still limited, especially in the US due to a lack of confidence towards biosimilars by some stakeholders; uncertainty about the interchangeability and substitution of biosimilars; and a hospital financing system that discourages the use of them. This yearâ€™s conference gathers biosimilars main players in the industry, representatives of pharmaceutical and biotechnological companies, professionals from governments, physicians and researchers to discuss updates in biosimilarsâ€™ development and regulatory restraints around them. Professionals and leaders will join an open conversation about barriers in developing biosimilars, cost of developing biosimilars; additionally, discover the way to introduce biosimilars to the market and provide sufficient knowledge for potential customers and consumers. Attendees will have the opportunity of networking with experts in the field while learning and sharing analytical views of the current biosimilars scene.
KEY PRACTICAL LEARNING POINTS OF THE SUMMIT:
An overview of the current biosimilars market
Barriers in developing biosimilars
Cost of developing biosimilars.
A summary of regulatory pathways in various geographic regions
How biosimilars are developing in different countries
An overview of approved biosimilars in the E.U., U.S., India, South Korea, and Latin America.
The market impact of biosimilars on their reference biologics
The top ten biologics on the focus of biosimilar developers
Ways to commercialize biosimilars
Implications of biosimilars inpatient treatment
WHO SHOULD ATTEND:
CEOs | CIOs|VPs | CTOs| Directors|Department Heads|Technical Analysts|Research Engineers |Specialists| Government officers specializing in:
Biosimilars Legal Affairs
Drug Pricing and Reimbursement
Preclinical and Clinical Development
Quality Affairs/ Quality Control
New Product Development and Pharmacovigilance
Infection and Immunity
Global Strategy and Antibody Engineering
Pharma Associations & Societies,
Biotechnology Experts/Business Entrepreneurs.
R&D, F&D Scientists
Intellectual Property Attorneys
Ph.D. and Post Doctorate Scholars
For More Information -
JSB Conference Events team
Mobile: +91 9987295242
Book Your Seat Now...